Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

BTIG cuts Gritstone Oncology PT to $17 from $31

BTIG reduced its price target for Gritstone Oncology (NASDAQ:GRTS) to $17 from $31, citing interim results from two Phase 1 clinical trials, GRANITE and SLATE, evaluating personalized and off-the-shelf neoantigen...

July 14, 2020

Markets

BTIG ups Vapotherm PT to $53 from $32

BTIG raised its price target for Vapotherm (NASDAQ:VAPO) to $53 from $32, citing a higher compound annual growth rate for revenue after a proprietary survey of U.S. hospitals that purchased the company’s Precision Flow...

July 13, 2020

Developments Markets

Mayo Clinic listed on TULSA center locator page, indicating Profound Medical’s first sale to a teaching hospital

The Mayo Clinic has just been listed as a new TULSA-PRO site, representing the first sale of the system to a teaching hospital by the technology’s developer, Profound Medical Profound Medical (TSX:PRN; NASDAQ:PROF)...

July 9, 2020

Markets

Maxim ups Biolife Solutions PT to $26 from $18

Maxim Group raised its price target for Biolife Solutions (NASDAQ:BLFS) to $26 from $18, citing a strengthening balance sheet, with management continuing to execute on its growth strategy. The stock closed at $17.59 on...

July 8, 2020

Markets

SVB Leerink cuts Radius Health to MP; PT to $17 from $34

SVB Leerink downgraded Radius Health (NASDAQ:RDUS) to “market perform” from “outperform” and halved its price target to $17 from $34, citing the company’s pipeline outlook. The stock closed at $14.06 on July 7. “We...

July 8, 2020

Markets

Maxim starts TFF Pharma at buy; PT $12

Maxim Group launched coverage of TFF Pharmaceuticals (NASDAQ:TFFP) with a “buy” rating and $12 price target. The stock closed at $6.22 on July 7. The company is using its thin film freezing (TFF) platform to develop two...

July 8, 2020

Markets

Chardan starts NGM Biopharmaceuticals at buy; PT $40

Chardan Capital Markets launched coverage of NGM Biopharmaceuticals (NASDAQ:NGM) with a “buy” rating and $40 price target. The stock closed at $19.01 on July 6. “We anticipate that NGM’s aldafermin is likely to...

July 7, 2020

Markets

AGP starts Organigram at buy; PT $4

Alliance Global Partners initiated coverage of Organigram Holdings (TSX:OGI) with a “buy” rating and price target of $4 (Canadian). The stock closed at $2.11 on July 6. “We view Organigram’s low-cost indoor [cannabis]...

July 7, 2020

Markets

Chardan starts Akero Therapeutics at buy; PT $79

Chardan Capital Markets launched coverage of Akero Therapeutics (NASDAQ:AKRO) with a “buy” rating and $79 price target. The stock closed at $34.96 on July 6. “We expect that Akero’s lead asset, efruxifermin, has...

July 7, 2020

Markets

BTIG starts Venus Concept at buy; PT $7

BTIG initiated coverage of Venus Concept (NASDAQ:VERO) with a “buy” rating and $7 price target. The stock closed at $3.52 on June 2. “It is not an easy time to be an aesthetics device company amidst the COVID-19...

July 6, 2020

Markets

SVB Leerink starts AdaptHealth at OP; PT $21

SVB Leerink launched coverage of AdaptHealth (NASDAQ:AHCO) with an “outperform” rating and $21 price target. The stock closed at $16.10 on June 30. Analyst Stephen Tanal writes that AdaptHealth is fast becoming the...

July 1, 2020

Markets

CohBar added to Russell 2000 index; raises $4.4-million in ATM offering

CohBar (NASDAQ:CWBR) was added to the small-cap Russell 2000 index during its latest reconstitution. The company also sold common stock through its existing at-the-market (ATM) offering, with net proceeds of about $4.4...

June 30, 2020

Markets

SVB Leerink starts Applied Molecular at OP; PT $32

SVB Leerink initiated coverage of Applied Molecular Transport (NASDAQ:AMTI) with an “outperform” rating and $32 price target. The stock closed at $25.80 on June 29. “We believe Applied’s emerging translocation...

June 30, 2020

Markets

HCW starts Merus NV at buy; PT $23

H.C. Wainwright launched coverage of Merus NV (NASDAQ:MRUS) with a “buy” rating and $23 price target. The stock closed at $15.80 on June 25. “Given the recent advances in structure-based design, bispecific antibodies...

June 26, 2020

Markets

BTIG ups Mersana Therapeutics PT to $32 from $21

BTIG raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $32 from $21, saying the company’s STING agonist antibody-drug conjugates look compelling on the evolving immunoncology landscape. The stock closed...

June 24, 2020

Markets

Brookline boosts life sciences equity research

Brookline Capital Markets added Sally Yanchus and Leah Rush Cann to its life sciences equity research team. With the addition of Ms. Yanchus and Ms. Cann, Brookline now has three publishing life sciences analysts, as...

June 24, 2020

Markets

HCW starts Aprea Therapeutics at neutral; PT $30

H.C. Wainwright initiated coverage of Aprea Therapeutics (NASDAQ:APRE) with a “neutral” rating and $30 price target. The stock closed at $37.90 on June 19. “We see more downside risk heading into pivotal data,” writes...

June 22, 2020

Markets

Ladenburg starts Forte Biosciences at buy; PT $60

Ladenburg Thalmann launched coverage of Forte Biosciences (NASDAQ:FBRX) with a “buy” rating and $60 price target. The stock closed at $14.31 on June 19. Forte is focused on the treatment of inflammatory skin diseases...

June 22, 2020

Markets

Maxim starts Annovis Bio at buy; PT $12

Maxim Group launched coverage of Annovis Bio (NYSE American:ANVS) with a “buy” rating and $12 price target. The stock closed at $5 on June 17. Annovis’ ANVS401 is a disease-modifying agent for chronic neurodegenerative...

June 18, 2020

Markets

Maxim starts Synthetic Biologics at buy; PT $1.50

Maxim Group initiated coverage of Synthetic Biologics (NYSE American:SYN) with a “buy” rating and price target of $1.50. The stock closed at 47 cents on June 17. The company is focused on the gut microbiome with two...

June 18, 2020

Markets

SVB Leerink starts Itamar Medical at OP; PT $30

SVB Leerink launched coverage of Itamar Medical (NASDAQ, TASE:ITMP) with an “outperform” rating and $30 price target. The stock closed at $16.01 on June 11. “We see Itamar as an underappreciated high growth/gross margin...

June 12, 2020

Markets

Stifel cuts Selecta Biosciences to hold with $4 PT

Stifel downgraded Selecta Biosciences (NASDAQ:SELB) to “hold” from “buy” with a price target of $4 after the company inked a licensing deal for its SEL-212 drug candidate for the treatment of severe chronic gout with...

June 12, 2020

Subscribe